MREO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1][3]. Group 1: Class Action Details - Investors who purchased Mereo ADSs between June 5, 2023, and December 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The lawsuit alleges that Mereo BioPharma provided investors with misleading information regarding the expected results of its Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5]. - The defendants reportedly made positive statements about setrusumab's potential to reduce annualized fracture rates while concealing adverse facts about the studies, which did not meet their primary endpoints [6].